With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.203662-51-5,4-Allyl-1-Boc-4-hydroxypiperidine,as a common compound, the synthetic route is as follows.
4.i) 4-Hydroxy-4-oxiranylmethyl-piperidine-1-carboxylic acid tert-butyl esterA solution of 4-allyl-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (3.1 g, 12.8 mmol, prepared according to J. Comb. Chem. 2002, 4, 125) in DCM and 0.3 M phosphate buffer (pH 8, 150 mL) was treated with mCPBA (3.5 g, 1.1 eq, 70%) and the mixture vigorously stirred at rt overnight. Further 3.5 g of mCPBA were added. After a total of 24 h, the phases were separated, the org. phase dried over MgSO4 and concentrated. CC (hex/EA 2:1 to 1:1 to EA) gave the desired intermediate as colourless oil (0.88 g, 26%).1H NMR (CDCl3) delta: 3.90-3.70 (m, 2H), 3.30-3.10 (m, 3H), 2.83 (dd, J=4.1, 4.9 Hz, 1H), 2.51 (dd, J=2.7, 4.9 Hz, 1H), 1.89 (dd, J=3.8, 14.5 Hz, 1H), 1.80-1.40 (m, 4H), 1.47 (s, 9H)., 203662-51-5
As the paragraph descriping shows that 203662-51-5 is playing an increasingly important role.
Reference£º
Patent; Actelion Pharmaceuticals Ltd; US2011/39823; (2011); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem